BioSpace News Archive

Drug Development

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

Oncopeptides AB presents data from the phase 3 OCEAN study, a direct head to head comparison of the efficacy and safety of melflufen plus dexamethasone and pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma, who are refractory to lenalidomide and have received 2-4 prior lines of therapy.

September 11, 2021
·
6 min read
Pharm Country

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data demonstrating robust prostate-specific antigen response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA® in the real-world clinical setting.

September 11, 2021
·
16 min read